4-Methyl-2-propyl-pyrrolidin | 90226-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-Methyl-2-propyl-pyrrolidin
• 英文别名: 2-n-Propyl-4-methylpyrrolidine；4-methyl-2-propylpyrrolidine
• CAS: 90226-39-4
• 化学式: C₈H₁₇N
• mdl: MFCD19219301
• 分子量: 127.23
• InChiKey: SAAXEKRBICMTDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use
  申请人：Farber Michael

  公开号：US20100311780A1

  公开（公告）日：2010-12-09

  There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. Also provided are compositions for increasing nitric oxide physiological levels in a subject, methods for increasing nitric oxide physiological levels in a subject, methods for improving a subject's muscle strength, athletic performances and/or lean body mass gain and or performance in a subject.

  本发明提供了一种新型氨基酸酯化合物，其中包括至少一个释放一氧化氮的基团和其药学上可接受的盐，并提供了至少包括一种氨基酸酯化合物的新型组合物，其中包括至少一个释放一氧化氮的基团，以及可选地，至少一种一氧化氮供体和/或至少一种治疗剂。此外，还提供了用于增加受试者体内一氧化氮生理水平的组合物，以及用于增加受试者体内一氧化氮生理水平、改善受试者肌肉力量、运动表现和/或瘦体重增加以及受试者表现的方法。
• Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
  申请人：JS INNOPHARM (SHANGHAI) LTD

  公开号：US11242334B2

  公开（公告）日：2022-02-08

  (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

  (I) 本文公开了式 I 化合物和/或其立体异构体、稳定同位素或药学上可接受的盐；以及这些化合物的治疗用途，它们是可能用于治疗可治疗疾病（如癌症）的激酶抑制剂，以及药物组合物，其中包含式 I 化合物和/或其立体异构体、稳定同位素或药学上可接受的盐，以及药学上可接受的载体。
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
  申请人：JS INNOPHARM (SHANGHAI) LTD

  公开号：US20200239438A1

  公开（公告）日：2020-07-30

  (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• [EN] HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION<br/>[FR] PRÉCURSEURS CONTENANT DU HAFNIUM POUR UN DÉPÔT EN PHASE VAPEUR
  申请人：AIR LIQUIDE

  公开号：WO2013177284A1

  公开（公告）日：2013-11-28

  Disclosed are hafnium-containing precursors and methods of synthesizing the same. The precursors may be used to deposit hafnium oxide, hafnium silicon oxide and hafnium-metal oxide containing layers using vapor deposition methods such as chemical vapor deposition or atomic layer deposition.
• [EN] TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION<br/>[FR] PRÉCURSEURS CONTENANT DU TITANE POUR UN DÉPÔT EN PHASE VAPEUR
  申请人：AIR LIQUIDE

  公开号：WO2013177292A1

  公开（公告）日：2013-11-28

  Disclosed are titanium-containing precursors and methods of synthesizing the same. The precursors may be used to deposit titanium oxide, titanium silicon oxide and titanium-metal oxide containing layers using vapor deposition methods such as chemical vapor deposition or atomic layer deposition.